相关实验视频

Updated: Jun 24, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

研究 lncRNA CTBP1-DT 作为一种潜在的治疗点,用于调节结直肠癌中的细胞功能

Ruizhi Fan^1,2, Teng Xu², Yuting Kuang³

¹Department of Gastrointestinal Surgery, The First Affiliated Hospital of Soochow University, No.188, Shizi Street, Suzhou, 215006, Jiangsu, China.

Discover oncology

|June 12, 2024

概括

长非编码RNA CTBP1-DT 在结直肠癌患者中升高,显示出诊断潜力. 它的击倒抑制了癌细胞活动和转移,表明CTBP1-DT是治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物标志物生物标志物

背景情况:

结肠直肠癌 (CRC) 是一个主要的全球健康问题.
早期发现和干预对于改善患者的治疗结果至关重要.
确定CRC的新型诊断和治疗点至关重要.

研究的目的:

调查长非编码RNA CTBP1-DT (CTBP1-DT) 在结直肠癌中的调控作用.
评估CTBP1-DT在结直肠癌患者的诊断意义.
在CRC中探索CTBP1-DT和microRNA-30a-5p (miR-30a-5p) 之间的关系.

主要方法:

用RT-qPCR比较了来自102名CRC患者和92名健康对照者的血清和瘤样本中的CTBP1-DT和miR-30a-5p水平.
细胞增殖,细胞亡和转移被评估使用CCK-8,流细胞计和Transwell测定.
进行了接收器操作特征 (ROC) 曲线分析,以评估诊断准确性.

主要成果:

与健康个体相比,CRC患者的血清CTBP1-DT水平显著升高.
在CRC患者中,血清miR-30a-5p表达的下调.
无论是CTBP1-DT还是miR-30a-5p都显示出CRC的诊断价值,联合检测显示出更高的准确性.
通过向miR-30a-5p,CTBP1-DT敲除抑制了CRC细胞的增殖和转移.

结论:

过度表达的CTBP1-DT显示出作为结直肠癌诊断生物标志物的潜力.
CTBP1-DT可以作为结直肠癌治疗的治疗点.
CTBP1-DT/miR-30a-5p轴在结直肠癌的进展中起作用.

关键词:

结肠直肠癌是一种癌症.诊断诊断诊断诊断诊断静音化 CTBP1-DTT 的情况.在cRNA CTBP1-DTT 中.在 miR-30a-5p 中使用.

更多相关视频

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...